Table 1. Baseline Demographics and Clinical Characteristics of the Validation Cohort.
| Variables* | Value |
|---|---|
| Mean age (year) (± SD) | 67.5 (± 12.1), range 35–95 |
| Sex, n (%) | |
| Male | 54 (63.5) |
| Female | 31 (36.5) |
| CRC location | |
| Colon | 63 (74.1) |
| Rectum | 22 (25.9) |
| CEA (ng/dL), median (IQR) | |
| CRLM group | 31.8 (8.4–123.5) |
| Non-CRLM group | 3.0 (1.9–8.3) |
| T stage (tumor invasion depth), n (%) | |
| T1–2 (confined to the bowel wall) | 12 (14.1) |
| T3–4 (beyond the bowel wall) | 73 (85.9) |
| N stage (nodal involvement), n (%) | |
| N- (node negative) | 25 (29.4) |
| N+ (node positive) | 60 (70.6) |
| M stage, n (%) | |
| M0 | 44 (51.8) |
| M1 | 41 (48.2) |
| Liver only | 25 (61.0) |
| Lung only | |
| Liver plus extrahepatic | 15 (36.6) |
| Size of CRLM (cm), mean | 2.2 (± 2.2), range 0.4–12.4 |
| Number of CRLM per patient, mean (± SD) | 2.5 (± 2.0), range 1–8 |
| Number of CRLM ≤ 1 cm, n (%)* | 27 (27.3) |
| Confirmatory method for CRML, n (%)* | |
| Histopathology after hepatic resection or percutaneous biopsy | 63 (63.6) |
| Suspicious MRI finding and follow-up imaging study | 36 (36.4) |
Values represent the number of subjects (%), median (IQR), or mean (± SD). *The total number of CRLMs was 99. CEA = serum carcinoembryonic antigen, CRC = colorectal cancer, CRLM = colorectal cancer liver metastasis, IQR = interquartile range, MRI = magnetic resonance imaging, SD = standard deviation